July 13, 2016
GenSight Biologics announces successful IPO on Euronext Paris
Media
July 12, 2016
Interim report H1 2016: Positive cash flow and EBIT. Expansion of Zubsolv® to new markets and improved market access position in the US.
July 08, 2016
Publication of prospectus, listing on Oslo Axess and subsequent offering
July 07, 2016
Oncopeptides Present Phase 2 Clinical Data at the European Hematology Association in Copenhagen, Denmark, June 2016
July 07, 2016
Orexo welcomes increased access to treatment for patients with opioid dependence in the US
July 07, 2016
Completion of private placement, registration of share capital increase
July 06, 2016
Targovax presents encouraging preclinical data on ONCOS-102
July 01, 2016
Targovax ASA: Applies for listing of its shares on Oslo Axess
July 01, 2016
Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma
June 30, 2016
Orexo signs license agreement with Mundipharma, which obtains ex-US global rights to Zubsolv®
